Paxlovid, Molnupiravir, Sotrovimab Appear Cost Effective To ICER; But Data, Price Could Change
Executive Summary
With the US government currently negotiating prices and drugs mostly going to high-risk patients, ICER’s draft ‘special assessment’ of COVID treatments offers an approach to adapting research on safety and effectiveness in order to provide guidance to clinicians, payers and other stakeholders.
You may also be interested in...
Califf’s Covid Twitter Communications Reveal Knowledge Gaps Partially Of FDA’s Own Making
FDA Commissioner’s recent Twitter threads highlight the challenges of discussing the unknowns of therapeutic interventions – and raise questions about why FDA isn’t doing more to close the information gaps.
ICER Gives Cold Shoulder To Merck/Ridgeback’s COVID-19 Pill
Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.
US Advanced Purchases For COVID Drugs A Model Post-Pandemic? Not Likely, Manufacturers Warn
Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.